neuro42, a medical technology company pioneering portable MRI, robot, and AI technologies, has secured undisclosed investments from angel investor Karna D Shinde.
This is Shinde’s third round of investment in the company. "The diagnostic and interventional capabilities of neuro42's MRI have the potential to transform the way challenging brain tumor cases are approached and treated," said Karna D Shinde, investor and strategic advisor.
neuro42 recently received USFDA clearance for its innovative diagnostic MRI product. "We are thrilled to announce the FDA clearance of our bedside MRI product. Our team has been focused on making a difference in patient care, and now we can finally arm healthcare providers with a valuable tool to improve accessibility to neuroimaging,” said Abhita Batra, Founder and Chief Strategy Officer of Neuro42.
As per the company, one of the primary drivers of innovation at Neuro42 is its ability to amplify the capabilities of neurosurgeons, particularly in complex and time-sensitive procedures such as the treatment of brain tumors and epilepsy.
In the neurointervention space, the need for advanced tools that can aid in precise diagnosis and targeted interventions is more critical than ever. The AI-driven tissue characterization feature that neuro42 is developing provides neurosurgeons with meaningful insights and enables them to make informed decisions and improve patient outcomes.
The commercialisation of neuro42's MRI and robotic platform is expected to have far-reaching implications for the field of neurosurgery, offering new possibilities for enhancing targeted treatment planning and patient care, according to a statement from the company.
